Ieq Capital LLC Sells 34,613 Shares of Becton, Dickinson and Company $BDX

Ieq Capital LLC cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 68.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,985 shares of the medical instruments supplier’s stock after selling 34,613 shares during the period. Ieq Capital LLC’s holdings in Becton, Dickinson and Company were worth $2,419,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at $25,000. SHP Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at $26,000. Prosperity Bancshares Inc acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at $29,000. Kohmann Bosshard Financial Services LLC bought a new position in Becton, Dickinson and Company in the fourth quarter valued at about $32,000. Finally, Meeder Asset Management Inc. increased its position in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the period. 86.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 11,704 shares of company stock worth $1,963,618. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX opened at $189.87 on Wednesday. The firm’s 50 day simple moving average is $163.37 and its 200 day simple moving average is $160.60. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The company has a market capitalization of $52.32 billion, a price-to-earnings ratio of 57.19, a P/E/G ratio of 13.44 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Barclays upped their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.